|Bid||4.8100 x 1000|
|Ask||5.3000 x 800|
|Day's range||4.7000 - 4.8500|
|52-week range||4.5100 - 11.2400|
|Beta (5Y monthly)||1.55|
|PE ratio (TTM)||N/A|
|Earnings date||24 Feb 2021|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||31 Oct 2014|
|1y target est||21.75|
The FDA bestows an Orphan Drug designation to Paratek's (PRTK) marketed drug Nuzyra for the treatment of infections caused by Nontuberculous Mycobacteria.
The big shareholder groups in Paratek Pharmaceuticals, Inc. ( NASDAQ:PRTK ) have power over the company. Large...
Thank you, operator, and good afternoon, everyone, and welcome to Paratek's second-quarter 2021 earnings and corporate update conference call. Participants on today's call are Evan Loh, chief executive officer; Adam Woodrow, president and chief commercial officer; and Randy Brenner, chief development and regulatory officer.